| Literature DB >> 36090579 |
Shuolin Li1, Jing Liu1, Yuan Yuan1, Aizhen Lu1, Fang Liu2, Li Sun3, Quanli Shen4, Libo Wang1.
Abstract
Kabuki syndrome (KS) is a rare genetic disorder characterized by dysmorphic facial features, skeletal abnormalities, and intellectual disability. KMT2D and KDM6A were identified as the main causative genes. To our knowledge, there exist no cases of KS, which were reported with pneumorrhagia. In this study, a 10-month-old male was diagnosed to have KS with typical facial features, skeletal anomalies, and serious postnatal growth retardation. Whole exome sequencing of the trio family revealed the presence of a de novo KMT2D missense variant (c.15143G > A, p. R5048H). The child was presented to the pediatric emergency department several times because of cough, hypoxemia, and anemia. After performing chest CT and fiberoptic bronchoscopy, we found that the child had a pulmonary hemorrhage. During research on the cause of pulmonary hemorrhage, the patient's anti-GBM antibodies gradually became positive, and the urine microalbumin level was elevated at the age of 12-month-old. After glucocorticoids and immunosuppressant therapy, the patient became much better. But he had recurrent pulmonary hemorrhage at the age of 16 months. Therefore, the patient underwent digital subtraction angiography (DSA). However, the DSA showed three abnormal bronchial arteries. This single case expands the phenotypes of patients with KS and Goodpasture's syndrome, which were found to have a de novo KMT2D missense variant.Entities:
Keywords: Goodpasture’s syndrome; KMT2D gene; Kabuki syndrome; missense variant; whole exome sequencing
Year: 2022 PMID: 36090579 PMCID: PMC9459111 DOI: 10.3389/fped.2022.933693
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
FIGURE 1Photographs of the patients in this study. (A,B) Showed makeup appearance. (C,D) Showed short fingers.
FIGURE 2Sanger sequencing of the case family. (A) Showed pedigree of the family. (B) A heterozygous G > A substitution was confirmed by sanger sequencing at position c.15143, changing an arginine codon into a histidine codon at amino acid position 5,048 (p.R5048H). (C) The variant is at the exon 48 of the KMT2D gene (NM_003482.3) but not at any domain of the KMT2D protein. PHD, plant homeotic domain; HMG-box, high mobility group-box; FYRN, FY- rich N-terminal domain; FYRC, FY-rich C- terminal domain; SET, Su (var) 3-9, enhancer-of-zeste and Trithorax domain.
FIGURE 3The imaging findings of this patient. (A) Chest X-ray (2021-08-11) showed a massive, diffuse bilateral large pulmonary consolidation. (B) The chest X-ray after therapy (2022-01-04). (C) The chest X-ray (2022-02-01) suggested extensive exudate. (D) After abnormal bronchial artery was embolized, the follow-up chest X-ray (2022-03-10) was significantly better than before. (E) Chest CT (2021-08-08) revealed increased patchy and flaky shadows were evident in both lungs, and a local thickening of bilateral pleura was seen. (F) The chest CT after therapy showed better than Figure 3E (2021-09-05). (G) The DSA showed right bronchial artery originated from the thoracic aorta. (H) The DSA showed left bronchial artery originating from the aortic arch.
Immunological phenotypes of KS in pediatric patients in literature.
| References | Infection susceptibility | Hypogamma-globulinemia | ↓ IgA | ↓ IgG | ↓ IgM | Autoimmune disease | ITP | AIHA | AITD | VT | AIN | Others |
| Di Candia et al. ( | 2/5 | 2/5 | 5/5 | 3/5 | 2/5 | – | – | – | 2/5 | 0/5 | – | – |
| So et al. ( | 3/21 | 0/21 | 0/21 | – | – | – | 2/21 | 1/21 | 1/21 | – | – | – |
| Margot et al. ( | 57/134 | 31/58 | – | – | – | 13/134 | 6/134 | 4/134 | 0/134 | 6/134 | – | – |
| Lindsley et al. ( | 9/13 | 3/13 | 9/13 | 5/13 | 4/13 | – | – | – | – | 1/13 | 1/13 | AIH |
| Stagi et al. ( | 51/59 | – | 36/54 | 21/51 | – | – | 17/59 | 7/59 | 3/59 | 4/59 | 2/59 | – |
| Armstrong et al. ( | – | 2/48 | – | – | – | – | 1/48 | – | – | – | – | – |
| Hoffman et al. ( | – | – | 15/19 | 8/19 | 2/19 | 3/19 | – | – | – | – | – | – |
| White et al. ( | 14/27 | – | – | – | – | – | – | – | – | – | – | – |
| matsumoto et al. ( | 73/116 | 1/116 | – | – | – | – | 1/116 | 1/116 | – | – | – | – |
| Wessels et al. ( | 114/24 | – | – | – | – | – | – | – | – | – | – | – |
“–” Not reported;↓ decreased.
AIHA, autoimmune hemolytic anemia; AITD, autoimmune thyroid disease; AIN, autoimmune neutropenia; AIH autoimmune hepatitis; ITP, Immune thrombocytopenic purpura; VT, vitiligo.